Physician profile
Paul Robison
NPI 1427010735
$31,313.80
in general payments reported to CMS, 2019-2025
12 companies · $1,380 in 2025
The $1,380 reported for 2025 was more than what a typical Thoracic Surgery (Cardiothoracic Vascular Surgery) provider received nationally (typical 2025 total: $796).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,898 · 2020: $16K · 2021: $9,228 · 2022: $1,607 · 2023: $108 · 2024: $161 · 2025: $1,380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $899 · Travel and Lodging: $749.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $899.32 |
| Travel and Lodging | $749.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $17,382.01 | 2019-2020 | |
| Bolton Medical INC | $11,141.51 | 2019-2024 | Treo Abdominal Stent-Graft System |
| Medtronic, INC. | $1,312.80 | 2025 | Endurant Iis, Corevalve Evolut R, Valiant Captivia |
| Abbott Laboratories | $956.41 | 2019 | |
| Getinge USA Sales, LLC | $160.85 | 2019-2021 | |
| Abiomed | $149.14 | 2021 | |
| Atricure, INC. | $67.01 | 2025 | Synergy Ablation System, Atriclip Laa Exclusion System, Isolator Surgical Ablation System |
| Janssen Pharmaceuticals, INC | $64.16 | 2021 | |
| Medtronic Vascular, INC. | $26.98 | 2019 | |
| Baxter Healthcare | $19.55 | 2021 | |
| Livanova USA, INC. | $18.07 | 2019 | |
| Biomerieux INC | $15.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Robison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.